随着美国总统大选临近,考虑到“打压药价”一直都是特朗普用于拉票的核心竞争力,素来“以金融思路做医药”的美国医疗保健业早在去年就陷入了焦灼期。一般情况下,“市场会在大选前夕大量抛售医药股,在大选结果出来之前,医药公司的估值往往会被削弱。”瑞银集团(UBS)的美国医疗行业分析师艾瑞克·波托克在9月22日发布的一份报告中写道:“近期市场对于医药股的反应正是延续了这一惯例。”
然而,波托克并不认为医药股在大选之后一定会走衰。他指出,与现下情况最相似的例子发生在2008-2009年大选期间,当年奥巴马也曾经承诺要把“医疗改革作为首要立法任务”,但其最终出台的《平价医疗法案》(Affordable Care Act)所起到的作用仍然相当有限,除去少数地区增加了有关限制条款,整个医疗市场几乎“完好无损”,医药股和保险股并没有产生多大的波动。相反,由于《平价医疗法案》要求绝大多数美国人购买医疗保险,随着民众对于医疗产品及医疗服务的需求不断增加,这些股票反而更为利好了。
换而言之,根据瑞银集团分析师的说法,美国医疗保健行业在2020年以后的走势将大概率会和2009年如出一辙,医药股投资者其实不必过分担忧。
那么在2009年以后的几年中,医药股的表现如何呢?事实上,在整个2009年至2015年期间,受益于稳定后的政策及不断增长的医疗需求,医药股的表现明显胜于整个大盘,在这五至六年的时间内,医疗保健行业的市盈率从原来标普500的0.8倍上升到了1.1倍。
值得注意的是,到了2016年特朗普一届总统大选之时,这种上涨态势便在顷刻间戛然而止了。随着医保政策再度走上舞台成为聚光灯下的讨论焦点,医药股再次陷入了风雨飘扬之中。所以,从历史的眼光来看,自去年开始的医疗保健企业的估值下挫完全就是一场恰如其分的“历史重演”。波托克指出,该行业近期的市盈率比2009年还低,还不到当年标普500的0.8倍。
“但实际上,我们仍然认为医疗保健业会重走2009年的老路。”波托克说道:“如果我们对政治形势的预测是正确的话,民主党依然会在日后制衡总统及参议院。特朗普所谓的承诺,大概率是难以实现的夸夸其谈。”药价很难被真的降下来,保险公司方面的改革阻力也很大,波托克预测“改革会以一个相对‘温和’的方式告终,届时医疗保健行业的估值也会回升。”
同样的道理也适用于医疗保健业外的其他领域,比如拜登也说过要在上任第一天就“提高企业税率”,但其实也只是雷声大雨点小的哄人手段而已。就像摩根大通所指出的那样,拜登根本不可能真的这么做,企业所可能承受的打击也未必有现在所想象的这么大。
那么在微观层面上,具体又有哪几个医疗公司可能会在未来受益呢?早在去年11月,《财富》杂志就总结过一辑“短期动荡但长期看好”的美国医药股名单,其中包括BD公司(Becton Dickinson)、豪洛捷公司(Hologic)、硕腾公司(Zoetis)、默沙东公司(Merck)以及联合健康集团(UnitedHealth Group)等。
以2009年为参照,波托克表示自己对医药股的未来“充满信心”。“一旦选举结果出来、政策得以落实,投资者对医疗保健行业的不确定心态就会大大降低。我们相信到那个时候,他们一定会看到医药股再次稳定且可靠的上涨,也会愿意赋予其更高的估值。”他补充道。“一言以蔽之,我们期待医药股在今后能够像奥巴马的《平价医疗法案》发布后的那五年一样,再创辉煌。”(财富中文网)
编译:陈怡轩
随着美国总统大选临近,考虑到“打压药价”一直都是特朗普用于拉票的核心竞争力,素来“以金融思路做医药”的美国医疗保健业早在去年就陷入了焦灼期。一般情况下,“市场会在大选前夕大量抛售医药股,在大选结果出来之前,医药公司的估值往往会被削弱。”瑞银集团(UBS)的美国医疗行业分析师艾瑞克·波托克在9月22日发布的一份报告中写道:“近期市场对于医药股的反应正是延续了这一惯例。”
然而,波托克并不认为医药股在大选之后一定会走衰。他指出,与现下情况最相似的例子发生在2008-2009年大选期间,当年奥巴马也曾经承诺要把“医疗改革作为首要立法任务”,但其最终出台的《平价医疗法案》(Affordable Care Act)所起到的作用仍然相当有限,除去少数地区增加了有关限制条款,整个医疗市场几乎“完好无损”,医药股和保险股并没有产生多大的波动。相反,由于《平价医疗法案》要求绝大多数美国人购买医疗保险,随着民众对于医疗产品及医疗服务的需求不断增加,这些股票反而更为利好了。
换而言之,根据瑞银集团分析师的说法,美国医疗保健行业在2020年以后的走势将大概率会和2009年如出一辙,医药股投资者其实不必过分担忧。
那么在2009年以后的几年中,医药股的表现如何呢?事实上,在整个2009年至2015年期间,受益于稳定后的政策及不断增长的医疗需求,医药股的表现明显胜于整个大盘,在这五至六年的时间内,医疗保健行业的市盈率从原来标普500的0.8倍上升到了1.1倍。
值得注意的是,到了2016年特朗普一届总统大选之时,这种上涨态势便在顷刻间戛然而止了。随着医保政策再度走上舞台成为聚光灯下的讨论焦点,医药股再次陷入了风雨飘扬之中。所以,从历史的眼光来看,自去年开始的医疗保健企业的估值下挫完全就是一场恰如其分的“历史重演”。波托克指出,该行业近期的市盈率比2009年还低,还不到当年标普500的0.8倍。
“但实际上,我们仍然认为医疗保健业会重走2009年的老路。”波托克说道:“如果我们对政治形势的预测是正确的话,民主党依然会在日后制衡总统及参议院。特朗普所谓的承诺,大概率是难以实现的夸夸其谈。”药价很难被真的降下来,保险公司方面的改革阻力也很大,波托克预测“改革会以一个相对‘温和’的方式告终,届时医疗保健行业的估值也会回升。”
同样的道理也适用于医疗保健业外的其他领域,比如拜登也说过要在上任第一天就“提高企业税率”,但其实也只是雷声大雨点小的哄人手段而已。就像摩根大通所指出的那样,拜登根本不可能真的这么做,企业所可能承受的打击也未必有现在所想象的这么大。
那么在微观层面上,具体又有哪几个医疗公司可能会在未来受益呢?早在去年11月,《财富》杂志就总结过一辑“短期动荡但长期看好”的美国医药股名单,其中包括BD公司(Becton Dickinson)、豪洛捷公司(Hologic)、硕腾公司(Zoetis)、默沙东公司(Merck)以及联合健康集团(UnitedHealth Group)等。
以2009年为参照,波托克表示自己对医药股的未来“充满信心”。“一旦选举结果出来、政策得以落实,投资者对医疗保健行业的不确定心态就会大大降低。我们相信到那个时候,他们一定会看到医药股再次稳定且可靠的上涨,也会愿意赋予其更高的估值。”他补充道。“一言以蔽之,我们期待医药股在今后能够像奥巴马的《平价医疗法案》发布后的那五年一样,再创辉煌。”(财富中文网)
编译:陈怡轩
Ever since 2019, the health care sector has been white-knuckling and preparing itself for what may be a volatile and uncertain election year for stocks. Historically, "the market reaction has been largely to sell much of the health care sector, lowering valuations until clarity arrives after the election," UBS's Americas health care analyst Eric Potoker wrote in a note on September 22. "The market’s current treatment of health care stocks falls into that familiar pattern."
Potoker argues the "most relevant" comparison for how the health care sector is shaping up today is the 2008–9 election, when, in early 2009, President Obama "made health reform a legislative priority, and a dark cloud enveloped the sector." But instead of massive, painful reforms to the sector that hurt health care and insurance stocks, he argues the passage of the Affordable Care Act (ACA) had a "relatively modest" impact on the sector, and, barring a few areas that saw increased regulation, "left health care markets largely intact" while actually increasing "overall demand for health care products and services" because of expanded health coverage.
But according to UBS, 2020 is shaping up to look a whole lot like 2009 for the sector—which could actually help put some investors' minds at ease.
That had a positive impact on health care stocks between 2009 and 2015, Potoker writes, as the health care sector "significantly outperformed the broader equity market, partly due to this added growth and the removal of policy uncertainty"—with health care trading up from a 0.8x relative price/earnings versus the S&P 500 up to a 1.1x relative P/E from late 2009 through mid-2015.
That outperformance, however, stopped short ahead of the 2016 election when health care was once more in the spotlight. This time around, as if "on cue," health care valuations started slumping last year, and the sector has even recently traded below its 2009 trough valuation compared to the S&P 500, he notes.
But today, "we actually think 2021 will play out very similarly to 2009 for the health care sector," UBS's Potoker argues. "If in fact the political prediction markets are correct and Democrats seize control of the presidency and the U.S. Senate...the rhetoric on changes to health care policy exceeds the reality of what can be accomplished," and in lieu of big reforms to drug pricing or insurers, he anticipates "modest reforms that will lift the overhang on health care valuations."
The “bark worse than the bite” argument for a Biden presidency is one that applies to other sectors beyond health care. JPMorgan, for one, has pointed out the hit to corporations may not be as bad because a President Biden likely won't raise the corporate tax rate on "day one," as he is currently declaring.
So what names are poised to benefit? Back in November of last year Fortune highlighted several health care stocks that may be more shielded from election woes and have since seen mixed but largely positive performance, like Becton Dickinson (down roughly 11% from November), Hologic (up 23%), Zoetis (up 32%), Merck (down 3.5%), and UnitedHealth Group (up 3.5%).
With 2009 as an example, Potoker says he remains "hopeful that the election outcome will begin the clearing process for the policy risk hovering over the sector," and with that clarity, "we think investors will reward the health care sector for its reliable growth with significantly higher valuations." Adds Potoker: "In short, we anticipate a period of strong health care stock performance similar to the five-year period following passage of the ACA."